Transactions
6
Insider / AbbVie Inc.
Alpern Robert J
Director at AbbVie Inc.
- Company
- AbbVie Inc.
- First filing on record
- October 2, 2025
- Latest trade on record
- March 31, 2026
- SEC filings
- EDGAR ↗
Alpern Robert J, Director at AbbVie Inc., has disclosed 6 transactions in ABT, ABBV since October 2, 2025: 0 purchases (0 open-market buys) and 0 sales, worth about $46K at the reported prices. The latest was filed April 2, 2026, 2 days after the trade; 2 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
3.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Alpern Robert J reported 4 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
2 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 6 | 298 | $46K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
| 2025 | 4 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ABT | Other A | March 31, 2026 | April 2, 2026 | 2d | 76 | $103 | $7,803 | derivative | Form 4 ↗ | |
| ABBV | Other A | March 31, 2026 | April 2, 2026 | 2d | 35 | $217 | $7,612 | derivative | Form 4 ↗ | |
| ABT | Other A | December 31, 2025 | January 5, 2026 | 5d | 62 | $125 | $7,768 | latederivative | Form 4 ↗ | |
| ABBV | Other A | December 31, 2025 | January 5, 2026 | 5d | 34 | $228 | $7,769 | latederivative | Form 4 ↗ | |
| ABT | Other A | September 30, 2025 | October 2, 2025 | 2d | 58 | $134 | $7,769 | derivative | Form 4 ↗ | |
| ABBV | Other A | September 30, 2025 | October 2, 2025 | 2d | 33 | $232 | $7,641 | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| April 2, 2026 | Form 4 | 0001448074-26-000007 | 1 | published | EDGAR ↗ |
| April 2, 2026 | Form 4 | 0001448074-26-000008 | 1 | published | EDGAR ↗ |
| January 5, 2026 | Form 4 | 0001448074-26-000003 | 1 | published | EDGAR ↗ |
| January 5, 2026 | Form 4 | 0001448074-26-000004 | 1 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0001448074-25-000012 | 1 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0001448074-25-000011 | 1 | published | EDGAR ↗ |
Other insiders at AbbVie Inc.
- Hart Brett J Director 19 rows
- Siatis Perry C EVP, GC AND SECRETARY 16 rows
- Stratton John G Director 14 rows
- Ford Robert B CHAIRMAN AND CEO 10 rows
- McKinstry Nancy Director 10 rows
- O'Grady Michael Chairman and CEO 10 rows
- Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER 9 rows
- AUSTIN ROXANNE S Director 7 rows
- Conroy Kevin T Director 7 rows
- Davis Jennifer L. Director 7 rows
Everyone on file, with contracts and lobbying under the company's name: AbbVie Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 6 | October 2, 2025 | April 2, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.